Advicenne to Present Additional Data on ADV7103 at the European Society for Paediatric Nephrology During Its 51st Annual Meeting

Advicenne’s management is participating as a partner of the Annual Meeting and held a Symposium on October 4^th, chaired by Elena Levtchenko. The company presents additional supporting data for ADV7103 in a poster “Assessment of Urine Parameters After Administration of ADV7103 in Healthy Adults and dRTA Patients” and can be found here.

The Advicenne Symposium, chaired by Dr Levtchenko is dedicated to “dRTA, toward a better management”. This symposium has given the opportunity to Fernando Santos (Oviedo, Spain) to share his clinician concerns about the transition period between childhood and adulthood for dRTA patients. Pr Detlef Bockenhauer (London, UK) presented the ESPN/ERKNet registry and Pierre Cochat (Lyon, France) presented the latest update on ADV7103 clinical program.

Dr. Luc-André Granier, co-founder, Chief Executive Officer and Medical Director of Advicenne comments “dRTA is a rare and devastating nephrological condition that can alter organ function, soften bones and affect the cardiovascular system, and for which there are currently no approved treatments. We remain committed to the continued development of this important program, including the initiation of the ARENA-2, pivotal phase III trial of ADV7103 in children and adults, for which the U.S. Food & Drug Administration cleared IND status on September 5^th, 2018.”

About the European Society for Paediatric Nephrology

The European Society for Paediatric Nephrology (https://espn-online.org) is a medical society organization that aims to promote research knowledge of paediatric nephrology through teaching, scientific meetings and other methods, for the benefit of children with renal disease. Advicenne is a sponsor of this year’s Annual Meeting.

About distal Renal Tubular Acidosis (dRTA)

dRTA is a disease that occurs when the kidneys do not properly remove acids from blood into urine. As a result, acid overload generates an unbalanced blood pH that trigger failure to thrive and rickets (a condition that affects bone development in children) as well as a range of additional clinical disorders such as a potassium deficiency (hypokalaemia) in blood serum, thus altering the function of several organs and most prominently affecting the cardiovascular system. In addition, a high concentration of calcium in blood and urine (hypercalcemia and hypercalciuria, respectively) can lead to kidney stones and calcinosis which may potentially cause renal impairment and ultimately renal failure. Either genetic or acquired as a result of autoimmune disease, dRTA is estimated to affect 30 000 patients in Europe and 20 000 in the US.

About Advicenne

Advicenne (Euronext: ADVIC) specializes in pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The French pharmaceutical company’s lead product, ADV7103, has achieved positive results in Europe in a pivotal phase III study in children and adults with distal Renal Tubular Acidosis (dRTA). In addition to this indication, ADV7103 is being developed for Cystinuria, an inherited renal tubulopathy.

Advicenne plans to file ADV7103 for European market authorization for dRTA in the second half of 2018 and anticipates its commercial launch in 2020. In the United States, the FDA has cleared ADV7103’s Investigational New Drug (IND) application to initiate a pivotal phase III clinical trial assessing the drug in dRTA patients. Commercial launch in the United States is anticipated for 2021.

Advicenne is listed on the regulated market of Euronext in Paris (ISIN: FR0013296746; Euronext ticker: ADVIC). Established in 2007, the company is headquartered in Nîmes, France. www.advicenne.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20181004005571/en/